GlassScriptPhysician profile
David A Elkins
NPI 1821159187
$1,230.81
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $256 · 2021: $46.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $468.86 | 2019-2020 | |
| Janssen Biotech, INC. | $262.70 | 2019-2020 | |
| Boston Scientific Corporation | $65.16 | 2019-2020 | |
| Pfizer INC. | $64.56 | 2019-2020 | |
| Allergan, INC. | $46.57 | 2019 | |
| Dendreon Pharmaceuticals LLC | $45.50 | 2019-2020 | |
| Amgen INC. | $39.19 | 2019 | |
| Coloplast Corp | $38.67 | 2020 | |
| Myovant Sciences INC. | $28.23 | 2021 | |
| Dornier Medtech America, INC | $26.21 | 2020 | |
| Agiliti Surgical, INC. | $24.58 | 2019 | |
| Endo Pharmaceuticals INC. | $23.31 | 2019 | |
| Janssen Scientific Affairs, LLC | $18.06 | 2019 | |
| Sun Pharmaceutical Industries INC. | $17.87 | 2019 | |
| Abbvie INC. | $17.35 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Orthoscience | $14.08 | 2021 | |
| Ferring Pharmaceuticals INC. | $13.28 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $12.81 | 2020 | |
| Travere Therapeutics, INC. | $3.82 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Elkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.